Low rate of production of apolipoproteins B100 and AI in 2 patients with anderson disease (chylomicron retention disease)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 6, 2012, Pages 1520-1525

  Ouguerram, Khadija ^a   Zaïr, Yassine ^a   Kasbi Chadli, Fatima ^a   Nazih, Hassane ^b   Bligny, Dominique ^c   Schmitz, Jacques ^d   Aparicio, Thomas ^e   Chétiveaux, Maud ^a   Magot, Thierry ^a   Aggerbeck, Laurence P ^f   Samson Bouma, Marie Elisabeth ^f   Krempf, Michel ^a  

^a CRNH AUVERGNE   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Saint Grégoire Private Hospital   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f INSERM   (France)

Author keywords

Anderson disease; Apolipoprotein AI; Apolipoprotein B100; Kinetic analysis; Modeling

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CARBON 13; CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; LEUCINE; LIPOPROTEIN A; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANDERSON DISEASE; ARTICLE; CASE REPORT; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPOCHOLESTEROLEMIA; LIPID ABSORPTION; LIPOPROTEIN BLOOD LEVEL; MALABSORPTION; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; CARBON ISOTOPES; CHOLESTEROL; DOWN-REGULATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOBETALIPOPROTEINEMIAS; KINETICS; LEUCINE; LIPOPROTEINS, VLDL; MALABSORPTION SYNDROMES; MALE; MODELS, BIOLOGICAL; MONOMERIC GTP-BINDING PROTEINS; MUTATION; PHENOTYPE; TRIGLYCERIDES;

EID: 84861532367     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.245076     Document Type: Article

References (37)

1. Olofsson SO, Borí J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med. 2005;258:395-410.
2. Peretti N, Roy CC, Sassolas A, Deslandres C, Drouin E, Rasquin A, Seidman E, Brochu P, Vohl MC, Labarge S, Bouvier R, Samson-Bouma ME, Charcosset M, Lachaux A, Levy E. Chylomicron retention disease: a long term study of two cohorts. Mol Genet Metab. 2009;97:136-142.
3. Peretti N, Sassolas A, Roy CC, Deslandres C, Charcosset M, Castagnetti J, Pugnet-Chardon L, Moulin P, Labarge S, Bouthillier L, Lachaux A, Levy E; Department of Nutrition-Hepatogastroenterology, Hôpital Femme Mére Enfant, Bron, UniversitéLyon 1; Department of Pediatrics, CHU Sainte-Justine Research Center, Universitéde Montréal. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J Rare Dis. 2010;5:24.
4. Georges A, Bonneau J, Bonnefont-Rousselot D, Champigneulle J, Rabés JP, Abifadel M, Aparicio T, Guenedet JC, Bruckert E, Boileau C, Morali A, Varret M, Aggerbeck LP, Samson-Bouma ME. Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease). Orphanet J Rare Dis. 2011;6:1.
5. Tarugi P, Averna M, Di Leo E, CefalüAB, Noto D, Magnolo L, Cattin L, Bertolini S, Calandra S. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007;195:e19-e27.
6. Anderson CM, Townley RR, Freeman M, Johansen P. Unusual causes of steatorrhoea in infancy and childhood. Med J Aust. 1961;48:617-622.
7. Bouma ME, Beucler I, Aggerbeck LP, Infante R, Schmitz J. Hypobetalipoproteinemia with accumulation of an apoprotein B-like protein in intestinal cells. Immunoenzymatic and biochemical characterization of seven cases of Anderson's disease. J Clin Invest. 1986;78:398-410.
8. Roy CC, Levy E, Green PH, Sniderman A, Letarte J, Buts JP, Orquin J, Brochu P, Weber AM, Morin CL. Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B. Chylomicron retention disease. Gastroenterology. 1987;92:390-399.
9. Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, Eichenbaum-Voline S, Rudling M, Myrdal U, Annesi G, Naik S, Meadows N, Quattrone A, Islam SA, Naoumova RP, Angelin B, Infante R, Levy E, Roy CC, Freemont PS, Scott J, Shoulders CC. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet. 2003;34:29-31.
10. Charcosset M, Sassolas A, Peretti N, Roy CC, Deslandres C, Sinnett D, Levy E, Lachaux A. Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein. Mol Genet Metab. 2008;93:74-84.
11. Silvain M, Bligny D, Aparicio T, Laforêt P, Grodet A, Peretti N, Ménard D, Djouadi F, Jardel C, BéguéJM, Walker F, Schmitz J, Lachaux A, Aggerbeck LP, Samson-Bouma ME. Anderson's disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities. Clin Genet. 2008;74:546-552.
12. Treepongkaruna S, Chongviriyaphan N, Suthutvoravut U, Charoenpipop D, Choubtum L, Wattanasirichaigoon D. Novel missense mutations of SAR1B gene in an infant with chylomicron retention disease. J Pediatr Gastroenterol Nutr. 2009;48:370-373.
13. CefalüAB, Calvo PL, Noto D, Baldi M, Valenti V, Lerro P, Tramuto F, Lezo A, Morra I, Cenacchi G, Barbera C, Averna MR. Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. Metab Clin Exp. 2010;59:463-467.
14. Annesi G, Aguglia U, Tarantino P, Annesi F, De Marco EV, Civitelli D, Torroni A, Quattrone A. SIL1 and SARA2 mutations in Marinesco-Sjren and chylomicron retention diseases. Clin Genet. 2007;71:288-289.
15. Siddiqi SA, Gorelick FS, Mahan JT, Mansbach CM 2nd. COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. J Cell Sci. 2003;116(Pt 2):415-427.
16. Dannoura AH, Berriot-Varoqueaux N, Amati P, Abadie V, Verthier N, Schmitz J, Wetterau JR, Samson-Bouma ME, Aggerbeck LP. Anderson's disease: exclusion of apolipoprotein and intracellular lipid transport genes. Arterioscler Thromb Vasc Biol. 1999;19:2494-2508.
17. Frénais R, Ouguerram K, Maugeais C, Mahot P, Maugére P, Krempf M, Magot T. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia. 1997;40:578-583.
18. Maugeais C, Ouguerram K, Krempf M, Maugeais P, Gardette J, Bigot E, Magot T. A minimal model using stable isotopes to study the metabolism of apolipoprotein B-containing lipoproteins in humans. Diabetes Metab. 1996;22:57-63.
19. Ouguerram K, Magot T, Zaïr Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther. 2003;306:332-337.
20. Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol. 1992;262(6 Pt 1):E968-E975.
21. Chétiveaux M, Nazih H, Ferchaud-Roucher V, Lambert G, Zaïr Y, Masson M, Ouguerram K, Bouhours D, Krempf M. The differential apoA-I enrichment of prebeta1 and alphaHDL is detectable by gel filtration separation. J Lipid Res. 2002;43:1986-1993.
22. Pont F, Duvillard L, Vergés B, Gambert P. Development of compartmental models in stable-isotope experiments: application to lipid metabolism. Arterioscler Thromb Vasc Biol. 1998;18:853-860.
23. Dagher FJ, Lyons JH, Finlayson DC, Shamsai J, Moore FD. Blood volume measurement: a critical study prediction of normal values: controlled measurement of sequential changes: choice of a bedside method. Adv Surg. 1965;1:69-109.
24. Craig WY, Nutik R, Cooper AD. Regulation of apoprotein synthesis and secretion in the human hepatoma Hep G2. The effect of exogenous lipoprotein. J Biol Chem. 1988;263:13880-13890.
25. Black DD, Hay RV, Rohwer-Nutter PL, Ellinas H, Stephens JK, Sherman H, Teng BB, Whitington PF, Davidson NO. Intestinal and hepatic apolipoprotein B gene expression in abetalipoproteinemia. Gastroenterology. 1991;101:520-528.
26. Braegger CP, Belli DC, Mentha G, Steinmann B. Persistence of the intestinal defect in abetalipoproteinaemia after liver transplantation. Eur J Pediatr. 1998;157:576-578.
27. Young SG, Cham CM, Pitas RE, Burri BJ, Connolly A, Flynn L, Pappu AS, Wong JS, Hamilton RL, Farese RV Jr. A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine. J Clin Invest. 1995;96:2932-2946.
28. Gusarova V, Brodsky JL, Fisher EA. Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. J Biol Chem. 2003;278:48051-48058.
29. Siddiqi SA. VLDL exits from the endoplasmic reticulum in a specialized vesicle, the VLDL transport vesicle, in rat primary hepatocytes. Biochem J. 2008;413:333-342.
30. Nemeth A, Myrdal U, Veress B, Rudling M, Berglund L, Angelin B. Studies on lipoprotein metabolism in a family with jejunal chylomicron retention. Eur J Clin Invest. 1995;25:271-280.
31. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35-46.
32. Sun LP, Seemann J, Goldstein JL, Brown MS. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII proteins. Proc Natl Acad Sci USA. 2007;104:6519-6526.
33. Levy E, Chouraqui JP, Roy CC. Steatorrhea and disorders of chylomicron synthesis and secretion. Pediatr Clin North Am. 1988;35:53-67.
34. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res. 1993;34:2207-2215.
35. Ikewaki K, Rader DJ, Zech LA, Brewer HB Jr. In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism. J Lipid Res. 1994;35:1809-1819.
36. Applebaum-Bowden D, Kobayashi J, Kashyap VS, Brown DR, Berard A, Meyn S, Parrott C, Maeda N, Shamburek R, Brewer HB Jr, Santamarina-Fojo S. Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest. 1996;97:799-805.
37. Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJ, Thomas CE, Jackson RL. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem. 1994;269:16376-16382.